Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient or patient's legal guardian must provide written informed consent prior to any protocol-related procedures being performed.~* The patient must have successfully completed Study ALID-003-99 (who received 21 of 26 consecutive weekly infusions).~* The patient has not experienced any safety issues that would contraindicate participation in the Extension study.~* A female patient of childbearing potential must have a negative pregnancy test at entry~Exclusion Criteria:~* The patient is pregnant or lactating.~* The patient has received an investigational drug within 30 days prior to the study enrollment.~* The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/Aldurazyme (Type: ACTIVE_COMPARATOR): Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
- Aldurazyme/Aldurazyme (Type: ACTIVE_COMPARATOR): Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.

Based on this trial design, predict the completion outcome and termination type (if applicable).